Esnault, Stephane http://orcid.org/0000-0001-7238-8671
Bernau, Ksenija
Torr, Elizabeth E.
Bochkov, Yury A.
Jarjour, Nizar N.
Sandbo, Nathan
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (NIH HL088594)
National Center for Advancing Translational Sciences (UL1TR000427)
American Thoracic Society (ATS Foundation)
Coalition for Pulmonary Fibrosis (Pulmonary Fibrosis Foundation Research Grant)
Comprehensive Cancer Center, University of Wisconsin (P30 CA014520)
University of Wisconsin-Madison (Development Funding)
Article History
Received: 28 June 2017
Accepted: 30 October 2017
First Online: 10 November 2017
Ethics approval and consent to participate
: The study protocol was approved by the University of Wisconsin-Madison Health Sciences Institutional Review Board (IRB). The use of blood eosinophils was approved by the IRB committee’s reference number: 2014–1481. The use of pulmonary fibroblasts was approved by IRB committee’s number: 2012–0061.
: Not applicable
: Dr. Nizar Jarjour is a consultant for Astra Zeneca in the areas of developing new therapeutic for asthma and COPD. The other authors declare that they have no competing interests related to this work.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.